Colleen Kelly, Attending Physician and Pediatric Hematologist/Oncologist at Dana-Farber Cancer Institute and Boston Children’s Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Pediatric Blood and Cancer, adding:
“Our new paper is out in Pediatric Blood and Cancer.
Gene therapy can be a transformative treatment for sickle cell disease. But its resource- and time-intensive nature may limit who can actually access it.
In our study, 60% of families with a child with sickle cell disease faced material hardship — food, housing, utility, or transportation insecurity — in the last year.